Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 7 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Zura Bio Ltd | ZURA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.05 | 07:00:53 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.05 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 6 | 7 | - | 2.00 - 12.9999 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 06:48:12 | 1 | $ 5.90 | USD |
Zura Bio Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 263.74M | 43.59M | - | 0 | -69.24M | -1.59 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Zura Bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ZURA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.79 | 6.35 | 4.52 | 5.64 | 276,723 | 1.26 | 26.30% |
| 1 Month | 3.48 | 6.35 | 3.13 | 4.50 | 273,478 | 2.57 | 73.85% |
| 3 Months | 3.64 | 6.35 | 2.00 | 3.21 | 328,999 | 2.41 | 66.21% |
| 6 Months | 4.23 | 6.35 | 2.00 | 3.59 | 259,776 | 1.82 | 43.03% |
| 1 Year | 5.52 | 12.9999 | 2.00 | 5.74 | 314,290 | 0.53 | 9.60% |
| 3 Years | 8.00 | 37.55 | 2.00 | 7.73 | 334,920 | -1.95 | -24.38% |
| 5 Years | 8.00 | 37.55 | 2.00 | 7.73 | 334,920 | -1.95 | -24.38% |
Zura Bio Description
| Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California. |
